Evidence map›Paper›PMID 25905473›Full record

ArticlePloS one2015

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.

Arjan van der Flier, Zhan Liu, Siyuan Tan, Kai Chen, Douglas Drager, Tongyao Liu, Susannah Patarroyo-White, Haiyan Jiang, David R Light

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. In Translation: FcRn across the Therapeutic Spectrum.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Article
  8. The Neonatal Fc Receptor (FcRn): A Misnomer?Frontiers in immunology · 2019
    Review
  9. Article
  10. Article
  11. Advances and innovations in haemophilia treatment.Nature reviews. Drug discovery · 2018
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Arjan van der FlierHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Zhan LiuHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Siyuan TanHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Kai ChenHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Douglas DragerHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Tongyao LiuHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Susannah Patarroyo-WhiteHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Haiyan JiangHematology Research, Biogen, Cambridge, Massachussets, United States of America.
David R LightHematology Research, Biogen, Cambridge, Massachussets, United States of America.
Biogen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently developed a longer lasting recombinant factor VIII-Fc fusion protein, rFVIIIFc, to extend the half-life of replacement FVIII for the treatment of people with hemophilia A. In order to elucidate the biological mechanism for the elongated half-life of rFVIIIFc at a cellular level we delineated the roles of VWF and the tissue-specific expression of the neonatal Fc receptor (FcRn) in the biodistribution, clearance and cycling of rFVIIIFc. We find the tissue biodistribution is similar for rFVIIIFc and rFVIII and that liver is the major clearance organ for both molecules. VWF reduces the clearance and the initial liver uptake of rFVIIIFc. Pharmacokinetic studies in FcRn chimeric mice show that FcRn expressed in somatic cells (hepatocytes or liver sinusoidal endothelial cells) mediates the decreased clearance of rFVIIIFc, but FcRn in hematopoietic cells (Kupffer cells) does not affect clearance. Immunohistochemical studies show that when rFVIII or rFVIIIFc is in dynamic equilibrium binding with VWF, they mostly co localize with VWF in Kupffer cells and macrophages, confirming a major role for liver macrophages in the internalization and clearance of the VWF-FVIII complex. In the absence of VWF a clear difference in cellular localization of VWF-free rFVIII and rFVIIIFc is observed and neither molecule is detected in Kupffer cells. Instead, rFVIII is observed in hepatocytes, indicating that free rFVIII is cleared by hepatocytes, while rFVIIIFc is observed as a diffuse liver sinusoidal staining, suggesting recycling of free-rFVIIIFc out of hepatocytes. These studies reveal two parallel linked clearance pathways, with a dominant pathway in which both rFVIIIFc and rFVIII complexed with VWF are cleared mainly by Kupffer cells without FcRn cycling. In contrast, the free fraction of rFVIII or rFVIIIFc unbound by VWF enters hepatocytes, where FcRn reduces the degradation and clearance of rFVIIIFc relative to rFVIII by cycling rFVIIIFc back to the liver sinusoid and into circulation, enabling the elongated half-life of rFVIIIFc.

Indexed as

AnimalsFactor VIIIHepatocytesHistocompatibility Antigens Class IMiceMice, KnockoutReceptors, FcReceptors, ScavengerRecombinant Fusion ProteinsTissue Distributionvon Willebrand FactorFactor VIIIFc receptor, neonatalHistocompatibility Antigens Class IReceptors, FcReceptors, ScavengerRecombinant Fusion Proteinsvon Willebrand Factor

Identifiers

PMID25905473
PMCPMC4408089
OpenAlexW2030100853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.